Pharming Group: A High-Risk, High-Reward Orphan Drug Innovator on the Cusp of Transformation
Overview
Pharming Group N.V. is a rare disease-focused biopharma headquartered in the Netherlands. Its lead asset, Ruconest, is a recombinant therapy for acute hereditary angioedema (HAE), occupying a unique position in the on-demand HAE treatment market. In 2023, Pharming launched Joenja (leniolisib), the first drug for APDS, an ultra-rare primary immunodeficiency. Ruconest is responsible for the bulk of current revenues, but Joenja is growing rapidly. Pharming’s business, initially U.S.-focused, is expanding geographically, and its pipeline is broadening through organic and acquisitive efforts. This transition from a single-product company to a multi-product rare disease specialist positions Pharming for further growth and risk mitigation.